The Charlotte Mecklenburg Hospital

1. GlaxoSmithKline, LLC. $1,186,745 63 payments
2. Boehringer Ingelheim Pharmaceuticals, Inc. $148,734 4 payments
3. Takeda Pharmaceuticals U.S.A., Inc. $147,613 28 payments
4. Merck Sharp & Dohme Corporation $12,287 2 payments
5. Global Blood Therapeutics, Inc. $9,000 1 payment

1. A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the E $674,510 19 payments
2. A Phase I Study of Niraparib in Combination With Standard Chemotherapy $177,179 1 payment
3. Phase Ib study with expansion cohorts $142,544 3 payments
4. A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the E $130,432 19 payments
5. A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investiga $130,294 12 payments
6. A Phase I/II Open-Label, Dose Escalation Study to Explore Safety and C $56,846 7 payments
7. The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT $35,083 4 payments
8. A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis $24,496 2 payments
9. A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease $21,525 2 payments
10. A Trial of AP32788 in Non-Small Cell Lung Cancer $19,168 3 payments

1. Other $124,811 15 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.